The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients

BACKGROUND: PrabotulinumtoxinA is a 900-kDa botulinum toxin type A produced by Clostridium botulinum. OBJECTIVES: The authors sought to investigate the safety of prabotulinumtoxinA for treatment of glabellar lines. METHODS: This was a multicenter, open-label, repeat-dose, 1-year phase II safety stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenc, Z Paul, Adelglass, Jeffrey M, Avelar, Rui L, Baumann, Leslie, Beer, Kenneth R, Cohen, Joel L, Cox, Sue Ellen, Dayan, Steven H, Dover, Jeffrey S, Downie, Jeanine B, Draelos, Zoe Diana, Goldman, Mitchel P, Gross, John E, Joseph, John H, Kaufman-Janette, Joely, Moy, Ronald L, Nestor, Mark, Schlessinger, Joel, Smith, Stacy R, Weiss, Robert A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Cosmetic Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598184/
https://www.ncbi.nlm.nih.gov/pubmed/33944913
http://dx.doi.org/10.1093/asj/sjaa382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598184/
https://www.ncbi.nlm.nih.gov/pubmed/33944913
http://dx.doi.org/10.1093/asj/sjaa382

Ejemplares similares